Palazestrant - ≥98% , CAS No.2092925-89-6

CAS: 2092925-89-6 Cat. No.: P757084 Summenformel: C₂₈H₃₆FN₃O Molekulargewicht: 449.60

GRADE & PURITY ≥98%

Synonyms

(1R,3R)-2-(2-Fluor-2-methylpropyl)-3-methyl-1-(4-((1-propylazetidin-3-yl)oxy)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol | 帕拉司群

Storage

Vor Licht geschützt, bei -20°C lagern

Shipped In

Eistruhe + Eispads

Übersicht

Palazestrant ist ein Antiöstrogen und antineoplastisches Mittel. Palazestrant kann die Aktivität von 17b-Östradiol (E2) mit einem IC50-Wert von 6,4 nM vollständig hemmen und die Proliferation von MCF7- und CAMA-1-Zellen mit einem IC50-Wert von 1,4-1,6 nM hemmen. Palazestrant kann ER+/HER2+-Krebs hemmen

Specifications

Synonyme

(1R,3R)-2-(2-Fluor-2-methylpropyl)-3-methyl-1-(4-((1-propylazetidin-3-yl)oxy)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol | 帕拉司群

Spezifikationen & Reinheit

≥98%

Storage

Vor Licht geschützt, bei -20°C lagern

Verschickt in

Eistruhe + Eispads

Aktionsart

ANTAGONIST

Reinheit

≥98%

Namen und Kennungen

• Molekulargewicht: 449.60

Chemische und physikalische Eigenschaften

• Empfindlichkeit: light sensitive

Häufig gestellte Fragen

What is the purity of this product?

This product is supplied at ≥98% purity (chemical assay). Lot-specific values are stated on the Certificate of Analysis.

How should this product be stored?

Store at ?20 °C, protected from light. The material is light-sensitive — keep it in its original opaque or amber container.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What are the CAS number, molecular formula and molecular weight?

The CAS Number is 2092925-89-6, the molecular formula is C28H36FN3O, and the molecular weight is 449.60 g/mol.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.